Special Issue

Pathology of Breast Cancer

Message from the Guest Editors

Breast carcinoma (BC) is the most common cancer and the second leading cause of cancer death in women, accounting for 12% of all new annual cancer cases worldwide. In the past two decades, advancements in molecular techniques have contributed to an improved understanding of BC biology, significant developments in the classification of breast cancer and enrichment with new molecular subtypes that have altered the daily practice of pathology. The prognostic and predictive utility of histopathologic parameters associated with the tumor microenvironment (TME), such as tumorinfiltrating lymphocytes (TILs), are also being elucidated, and new protocols have been devised for the pathologic assessment of BC specimens that have undergone neoadjuvant therapy. In this Special Issue, we are interested in papers that focus on the current diagnostic approaches and developments in the pathology of BC, the surgical advancements in the management of the breast and the axilla and novelties in oncological and radiotherapeutic management that impact our practices. Original articles and systematic reviews are equally welcome.

Guest Editors

Prof. Dr. Vasiliki Zolota

- 1. Department of Pathology, School of Medicine, University of Patras, 26504 Patras, Greece
- 2. Department of Pathology, University Hospital of Patras, 26504 Patras. Greece

Prof. Dr. Helen Kourea

Department of Pathology, School of Medicine, University of Patras, 26504 Patra, Greece

Deadline for manuscript submissions

closed (10 October 2023)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/131476

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

